Quantum-First Trial: <i>FLT3</i>-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
Mark J. Levis(Sidney Kimmel Cancer Center), Alexander E. Perl(University of Pennsylvania), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Arnaud Lesegretain(Daiichi Sankyo (United States)), Radovan Vrhovac(University Hospital Centre Zagreb), Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), James Hanyok(Daiichi Sankyo (United States)), Elżbieta Patkowska(Institute for Transfusion Medicine), Jaime E. Connolly Rohrbach(Daiichi Sankyo (United States)), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Liu(Shihezi University), Hee‐Je Kim(St. Mary's Hospital), Павел Зак(University Hospital Hradec Králové), Hervé Dombret(University of London Institute in Paris), Ken C. N. Chang(Daiichi Sankyo (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 9
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k